Blackstone Pumps $750 Million into Moderna's Flu Vaccine Endeavor
In a notable move to invigorate the landscape of flu vaccinations, Blackstone Life Sciences has committed an investment of up to $750 million to support Moderna's mRNA-based flu vaccine programs. This substantial investment underscores the burgeoning interest and belief in the potential of mRNA technology, originally popularized by its use in COVID-19 vaccines, to revolutionize the prevention of seasonal influenza.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
